Protocol Ledger

NCT07095452 · Phase II/III · RECRUITING

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Dia

Interventional Phase II/III clinical trial protocol NCT07095452 sponsored by AbbVie in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-08 Enrollment: 680 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07095452
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)680 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07095452
Protocol FieldVerified Registry Value
NCT IdentifierNCT07095452
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment680 participants (ESTIMATED)
Registered Start Date2026-01-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07095452
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->
Mayo Clinic RochesterRochester, MNOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI